Soon after thedevelopment of the third generation of Als, (anastrozole, letrozole and exemestane) withlower toxicity, the Als became the adjuvant endocrine treatment of choice for the ER+postmenopausal breast cancer patients (Dowsett etal. 2010). Here, ESR1 is linked to breast carcinoma.